Merck Shuts Down Covid Vaccine Program After Lackluster Data

Source: Bloomberg

Merck is discontinuing development of its two experimental Covid-19 vaccines after early trial data showed they failed to generate immune responses comparable to a natural infection or existing vaccines, according to a Bloomberg report.

The U.S. drug giant, which has a history of successfully developing vaccines, had adopted a different strategy from rivals Pfizer, Moderna, and Johnson & Johnson, using a more traditional approach of focusing on shots based on weakened viruses.

Read the full article.

Related Content